Search icon

TG THERAPEUTICS, INC.

Company Details

Name: TG THERAPEUTICS, INC.
Jurisdiction: New York
Legal type: FOREIGN BUSINESS CORPORATION
Status: Active
Date of registration: 02 Nov 1999 (26 years ago)
Entity Number: 2435400
ZIP code: 12207
County: New York
Place of Formation: Delaware
Address: 80 STATE STREET, ALBANY, NY, United States, 12207
Principal Address: 3020 carrington mill blvd., suite 475, MORRISVILLE, NC, United States, 27560

Agent

Name Role Address
CORPORATION SERVICE COMPANY Agent 80 STATE STREET, ALBANY, NY, 12207

DOS Process Agent

Name Role Address
C/O CORPORATION SERVICE COMPANY DOS Process Agent 80 STATE STREET, ALBANY, NY, United States, 12207

Chief Executive Officer

Name Role Address
MICHAEL S. WEISS Chief Executive Officer 3020 CARRINGTON MILL BLVD., SUITE 475, MORRISVILLE, NC, United States, 27560

Form 5500 Series

Employer Identification Number (EIN):
363898269
Plan Year:
2012
Number Of Participants:
7
Sponsors Telephone Number:

History

Start date End date Type Value
2024-09-10 2024-09-10 Address 2 GANSEVOORT STREET, NEW YORK, NY, 10014, USA (Type of address: Chief Executive Officer)
2024-09-10 2024-09-10 Address 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY, 10014, USA (Type of address: Chief Executive Officer)
2024-09-10 2024-09-10 Address 3020 CARRINGTON MILL BLVD., SUITE 475, MORRISVILLE, NC, 27560, USA (Type of address: Chief Executive Officer)
2023-11-02 2024-09-10 Address 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY, 10014, USA (Type of address: Chief Executive Officer)
2023-11-02 2023-11-02 Address 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY, 10014, USA (Type of address: Chief Executive Officer)

Filings

Filing Number Date Filed Type Effective Date
240910000102 2024-09-09 AMENDMENT TO BIENNIAL STATEMENT 2024-09-09
231102002656 2023-11-02 BIENNIAL STATEMENT 2023-11-01
211102002028 2021-11-02 BIENNIAL STATEMENT 2021-11-02
200514060248 2020-05-14 BIENNIAL STATEMENT 2019-11-01
150622000212 2015-06-22 CERTIFICATE OF AMENDMENT 2015-06-22

Trademarks Section

Serial Number:
97715586
Mark:
BRIUMVI UBLITUXIMAB-XIIY 150 MG/6ML INJECTION FOR IV
Status:
REGISTERED
Mark Type:
TRADEMARK
Application Filing Date:
2022-12-13
Mark Drawing Type:
Illustration: Drawing or design which also includes word(s)/letter(s)/number(s)
Mark Literal Elements:
BRIUMVI UBLITUXIMAB-XIIY 150 MG/6ML INJECTION FOR IV

Goods And Services

For:
pharmaceutical preparations for human use, namely, pharmaceutical preparations for the prevention and treatment of central nervous system disorders, multiple sclerosis, autoimmune diseases and B-cell mediated non-oncological diseases, the foregoing featuring monoclonal antibodies
First Use:
2023-06-12
International Classes:
005 - Primary Class
Class Status:
Active
Serial Number:
97715574
Mark:
BRIUMVI UBLITUXIMAB-XIIY 150 MG/6ML INJECTION FOR IV
Status:
REGISTERED
Mark Type:
TRADEMARK
Application Filing Date:
2022-12-13
Mark Drawing Type:
Illustration: Drawing or design which also includes word(s)/letter(s)/number(s)
Mark Literal Elements:
BRIUMVI UBLITUXIMAB-XIIY 150 MG/6ML INJECTION FOR IV

Goods And Services

For:
pharmaceutical preparations for human use, namely, pharmaceutical preparations for the prevention and treatment of central nervous system disorders, multiple sclerosis, autoimmune diseases and B-cell mediated non-oncological diseases, the foregoing featuring monoclonal antibodies
First Use:
2023-06-12
International Classes:
005 - Primary Class
Class Status:
Active
Serial Number:
97495097
Mark:
UMKEYVA
Status:
ABANDONED-FAILURE TO RESPOND OR LATE RESPONSE
Mark Type:
TRADEMARK
Application Filing Date:
2022-07-08
Mark Drawing Type:
Standard character mark
Mark Literal Elements:
UMKEYVA

Goods And Services

For:
pharmaceutical preparations for human use
International Classes:
005 - Primary Class
Class Status:
Active
Serial Number:
97495091
Mark:
UPKYA
Status:
ABANDONED-FAILURE TO RESPOND OR LATE RESPONSE
Mark Type:
TRADEMARK
Application Filing Date:
2022-07-08
Mark Drawing Type:
Standard character mark
Mark Literal Elements:
UPKYA

Goods And Services

For:
pharmaceutical preparations for human use
International Classes:
005 - Primary Class
Class Status:
Active
Serial Number:
97418597
Mark:
UBLI
Status:
THIRD EXTENSION - GRANTED
Mark Type:
TRADEMARK
Application Filing Date:
2022-05-19
Mark Drawing Type:
Standard character mark
Mark Literal Elements:
UBLI

Goods And Services

For:
pharmaceutical preparations and substances for the treatment of oncological, autoimmune and central nervous system diseases and disorders
International Classes:
005 - Primary Class
Class Status:
Active

Court Cases

Court Case Summary

Filing Date:
2022-07-18
Status:
Terminated
Nature Of Judgment:
no monetary award
Jury Demand:
Plaintiff demands jury
Nature Of Suit:
Securities, Commodities, Exchange

Parties

Party Name:
SHAPIRO,
Party Role:
Plaintiff
Party Name:
TG THERAPEUTICS, INC.
Party Role:
Defendant

Court Case Summary

Filing Date:
2018-10-04
Status:
Terminated
Nature Of Judgment:
no monetary award
Jury Demand:
Plaintiff demands jury
Nature Of Suit:
Securities, Commodities, Exchange

Parties

Party Name:
REINMANN,
Party Role:
Plaintiff
Party Name:
TG THERAPEUTICS, INC.
Party Role:
Defendant

Court Case Summary

Filing Date:
2017-01-24
Status:
Terminated
Nature Of Judgment:
no monetary award
Jury Demand:
Plaintiff demands jury
Nature Of Suit:
Securities, Commodities, Exchange

Parties

Party Name:
WYZGOSKI
Party Role:
Plaintiff
Party Name:
TG THERAPEUTICS, INC.
Party Role:
Defendant

Date of last update: 31 Mar 2025

Sources: New York Secretary of State